Kate Haviland is a life sciences executive with more than 20 years of experience and leadership within the biopharmaceutical industry, as well as a substantial background in scaling high-growth organizations, strategic business development, portfolio strategy, investor relations, and commercial execution. Kate served as President and Chief Executive Officer of Blueprint Medicines from 2022 through the acquisition of Blueprint in July of 2025. Previously, she served as Chief Operating Officer from January 2019 to April 2022, and as Chief Business Officer from January 2016 to January 2019. Over this time, she was the founding chair of the portfolio management team, formed and executed business development strategy, drove global capital investment plans, and played a key role in capital market financings. In addition, she worked to drive the transformative growth of the company and support its evolution into a fully integrated business by developing and providing ongoing management of critical functions, including corporate development, corporate affairs, commercial strategy, international, technical operations, portfolio strategy and management, and information systems. Prior to joining Blueprint Medicines, Kate held leadership roles focused on building emerging, high-growth companies and advancing the development of innovative therapies in oncology and rare diseases as Vice President, Rare Diseases and Oncology Program Leadership at Idera Pharmaceuticals, Head of Commercial Development at Sarepta Therapeutics, Executive Director of Commercial Development at PTC Therapeutics, and roles in both corporate development and project management at Genzyme. She holds a B.A. from Wesleyan University with a double major in Molecular Biology/Biochemistry and Economics and an M.B.A. from Harvard Business School. Kate currently serves as chair of the board of directors at Fulcrum Therapeutics, as an independent director on the board of directors at Bicara Therapeutics, as a member of the board of directors at Biotechnology Innovation Organization (BIO) and as a trustee of the Boston Museum of Science.